Skip to Content

Generic Luvox CR Availability

See also: Generic Luvox

Luvox CR is a brand name of fluvoxamine, approved by the FDA in the following formulation(s):

LUVOX CR (fluvoxamine maleate - capsule, extended release;oral)

  • Manufacturer: JAZZ PHARMS
    Approval date: February 28, 2008
    Strength(s): 100MG [AB], 150MG [RLD] [AB]

Has a generic version of Luvox CR been approved?

A generic version of Luvox CR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Luvox CR and have been approved by the FDA:

fluvoxamine maleate capsule, extended release;oral

  • Manufacturer: ACTAVIS ELIZABETH
    Approval date: April 23, 2013
    Strength(s): 100MG [AB]
  • Manufacturer: ACTAVIS ELIZABETH
    Approval date: November 18, 2013
    Strength(s): 150MG [AB]
  • Manufacturer: ANCHEN PHARMS
    Approval date: March 13, 2013
    Strength(s): 100MG [AB], 150MG [AB]
  • Manufacturer: TORRENT PHARMS LTD
    Approval date: October 31, 2014
    Strength(s): 100MG [AB], 150MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Luvox CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
    Patent 7,465,462
    Issued: December 16, 2008
    Inventor(s): Jeary; Theresa Ann & Morrissey; Catherine Ann & Stark; Paul
    Assignee(s): Elan Pharma International Limited
    A multiparticulate controlled release selective serotonin reuptate inhibitor (SSRI) formulation for oral administration is provided. The formulation includes particles of an SSRI or a pharmaceutically acceptable salt thereof, which are coated with a rate-controlling polymer that allows controlled release of the SSRI over a period of not less than about 12 hours after oral administration. The rate controlling polymer includes a film-forming water-insoluble polymer, or a mixture of a film-forming water-insoluble polymer and a film-forming water-soluble polymer.
    Patent expiration dates:
    • May 10, 2020
      Drug product


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.